No Data
Foghorn Therapeutics Price Target Lowered to $4 From $9 at Morgan Stanley
H.C. Wainwright Maintains Foghorn Therapeutics(FHTX.US) With Buy Rating, Cuts Target Price to $13
Morgan Stanley Maintains Foghorn Therapeutics(FHTX.US) With Hold Rating, Maintains Target Price $9
Foghorn Therapeutics: Hold Rating Amid Strategic Pivot and Uncertainty in Drug Development
12 Health Care Stocks Moving In Monday's Pre-Market Session
Jefferies Maintains Buy on Foghorn Therapeutics, Lowers Price Target to $14
loading...
No Data
Daily Investors : Hey I started a Bio Tech group, I know your on the same exact thing. If you want in you can. It is only for Bio and Major Pharm. But just what iv put in their over the weekend and today. Def worth it, if you want in send me a FR and I'll add you in
Daily Investors : * Editas Medicine laid off 65% of its workforce after failing to find a partner for its reni-cel program.
* Medtronic's latest PillCam completed its first patient procedure.
* AbbVie acquired oral peptide biotech Nimble for $200 million.
* Novartis paid PTC $1 billi...
Trytosaveabit OP Daily Investors : Thank you! I’ll have to think it over. I’m so busy already that I’m not sure if I’ll be able to contribute much! But again thank you